EGFR and non-small cell lung carcinoma: By adding AZD3759 (Ahn et al., 2017), an EGFR inhibitor which is primarily designed to treat brain metastasis of EGFR‐positive NSCLC, the patient’s brain progression was effectively controlled for 9 months.